Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
HilleVax, Inc (HLVX)
NASDAQ:HLVX
HilleVax, Inc (HLVX) Stock Price & Analysis
56 Followers
HLVX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.55 - $20.22
Previous Close$1.77
Volume1.28M
Average Volume (3M)932.20K
Market Cap
$88.01M
Enterprise Value-$133.43M
Total Cash (Recent Filing)$272.74M
Total Debt (Recent Filing)$51.31M
Price to Earnings (P/E)―
Beta1.38
Next Earnings
Aug 07, 2024EPS Estimate
-$0.78Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.29
Shares Outstanding49,720,943
10 Day Avg. Volume200,502
30 Day Avg. Volume932,202
Standard Deviation0.20
R-Squared0.04
Alpha-0.00577
Financial Highlights & Ratios
Price to Book (P/B)2.45
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-7.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda2.16
Forecast
1Y Price Target
$3.00Price Target Upside58.73% Upside
Rating ConsensusHold
Number of Analyst Covering5
HilleVax, Inc News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceThe company’s current cash balance is approximately $215M net of $25M debt repayment, which equates to approx. $4/share.
Market PotentialThe initial HIL-214 infant commercial opportunity is estimated at $600-800M in the US with in-line pricing to other infant vaccines.
Vaccine DevelopmentPositive results in the NEST-IN1 trial in infants could lead to timely Phase 3 development for both infants and older adults.
Bears Say
Investor SentimentThe company is unlikely to receive much near-term support from investors due to the NEST-IN1 data and the high resource demands of further development.
Stock RatingFollowing disappointing top-line data from the P2b NEST-IN1 trial resulting in the discontinuation of HIL-214 development in infants, the stock rating is downgraded from Buy to Hold.
Study ResultsThe Ph2b NEST-IN1 study of norovirus vaccine HIL-214 in infants showed only 5% efficacy vs. expectations of >70% and also failed on secondary endpoints.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
HLVX FAQ
What was HilleVax, Inc’s price range in the past 12 months?
HilleVax, Inc lowest stock price was $1.55 and its highest was $20.22 in the past 12 months.
What is HilleVax, Inc’s market cap?
Currently, no data Available
When is HilleVax, Inc’s upcoming earnings report date?
HilleVax, Inc’s upcoming earnings report date is Aug 07, 2024 which is in 16 days.
How were HilleVax, Inc’s earnings last quarter?
HilleVax, Inc released its earnings results on May 09, 2024. The company reported -$0.97 earnings per share for the quarter, missing the consensus estimate of -$0.815 by -$0.155.
Is HilleVax, Inc overvalued?
According to Wall Street analysts HilleVax, Inc’s price is currently Undervalued.
Does HilleVax, Inc pay dividends?
HilleVax, Inc does not currently pay dividends.
What is HilleVax, Inc’s EPS estimate?
HilleVax, Inc’s EPS estimate is -$0.78.
How many shares outstanding does HilleVax, Inc have?
HilleVax, Inc has 49,720,943 shares outstanding.
What happened to HilleVax, Inc’s price movement after its last earnings report?
HilleVax, Inc reported an EPS of -$0.97 in its last earnings report, missing expectations of -$0.815. Following the earnings report the stock price went down -1.072%.
Which hedge fund is a major shareholder of HilleVax, Inc?
Among the largest hedge funds holding HilleVax, Inc’s share is Deerfield Management Company, LP. It holds HilleVax, Inc’s shares valued at 67M.
---
HilleVax, Inc Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$3.00 (58.73% Upside)
$3.00 (58.73% Upside)
Hedge Fund Trend
Increased
By 132.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.7%
Last 30 Days ▲ 7.9%
Last 30 Days ▲ 7.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-87.81%
12-Months-Change
Fundamentals
Return on Equity
-59.55%
Trailing 12-Months
Asset Growth
4.39%
Trailing 12-Months
Company Description
HilleVax, Inc
HilleVax Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.
---
HLVX Stock 12 Month Forecast
Average Price Target
$3.00
▲(58.73% Upside)
Technical Analysis
Best Analysts Covering HLVX
1 Year
1 Year Success Rate
6/13 ratings generated profit
1 Year Average Return
-19.02%
assigned a buy rating 15 days ago
Copying David Risinger's trades and holding each position for 1 Year would result in 46.15% of your transactions generating a profit, with an average return of -19.02% per trade.
---